Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS)

During the 2023 ASCO Annual Meeting, researchers presented overall survival results from the phase 3 PRECIOUS trial of pertuzumab retreatment with or without trastuzumab and chemotherapy in patients with HER2-positive locally advanced/metastatic breast cancer previously treated with pertuzumab-containing regimens, which showed that the addition of pertuzumab to trastuzumab/chemotherapy significantly improved OS compared to trastuzumab/chemotherapy alone.